Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Rome, Italy.
Dipartimento di Chimica e Tecnologia del Farmaco, "Sapienza" Università di Roma, Rome, Italy.
Drug Test Anal. 2021 Apr;13(4):770-784. doi: 10.1002/dta.2985. Epub 2020 Dec 8.
The detection of 19-norsteroids abuse in doping controls currently relies on the determination of 19-norandrosterone (19-NA) by gas chromatography-tandem mass spectrometry (GC-MS/MS). An additional confirmatory analysis by gas chromatography coupled to isotope ratio mass spectrometry (GC-C-IRMS) is performed on samples showing 19-NA concentrations between 2.5 and 15 ng/ml and not originated from pregnant female athletes or female treated with 19-norethisterone. 19-Noretiocholanolone (19-NE) is typically produced to a lesser extent as a secondary metabolite. The aim of this work was to improve the GC-C-IRMS confirmation procedure for the detection of 19-norsteroids misuse. Both 19-NA and 19-NE were analyzed as target compounds (TCs), whereas androsterone (A), pregnanediol (PD), and pregnanetriol (PT) were selected as endogenous reference compounds (ERCs). The method was validated and applied to urine samples collected by three male volunteers after the administration of nandrolone-based formulations. Before the instrumental analysis, urine samples (<25 ml) were hydrolyzed with β-glucuronidase from Escherichia coli and extracted with n-pentane. Compounds of interest were purified through a single (for PT) or double (for 19-NE, 19-NA, A, and PD) liquid chromatographic step, to reduce the background noise and eliminate interferences that could have affect the accuracy of δ C values. The limit of quantification (LOQ) of 2 ng/ml was ensured for both 19-NA and 19-NE. The 19-NE determination could be helpful in case of "unstable" urine samples, in late excretion phases or when coadministration with 5α-reductase inhibitors occur.
目前,在兴奋剂检测中,19-去甲雄甾烷类物质的滥用检测依赖于气相色谱-串联质谱(GC-MS/MS)测定 19-去甲雄烷酮(19-NA)。对于浓度在 2.5 至 15ng/ml 之间且非来自怀孕女运动员或接受 19-去甲睾酮治疗的女性运动员的尿液样本,需进行气相色谱-同位素比质谱(GC-C-IRMS)的附加确证分析。19-去甲雄烯醇酮(19-NE)通常作为次要代谢产物产生。本研究旨在改进用于检测 19-去甲雄烷类物质滥用的 GC-C-IRMS 确证程序。19-NA 和 19-NE 均被分析为目标化合物(TCs),而雄酮(A)、孕烷二醇(PD)和孕烷三醇(PT)则被选为内源性参考化合物(ERCs)。该方法经过验证后,应用于三名男性志愿者在接受基于诺龙的制剂治疗后收集的尿液样本。在仪器分析之前,尿液样本(<25ml)用大肠杆菌的β-葡萄糖醛酸酶进行水解,并用正戊烷提取。通过单一(用于 PT)或双重(用于 19-NE、19-NA、A 和 PD)液相色谱步骤对感兴趣的化合物进行纯化,以降低背景噪声并消除可能影响δC 值准确性的干扰。19-NA 和 19-NE 的定量限(LOQ)均确保为 2ng/ml。在“不稳定”尿液样本、晚期排泄阶段或与 5α-还原酶抑制剂共同给药时,19-NE 的测定可能会有所帮助。